• The aim of this study is to evaluate the prognostic impact of myeloid-derived suppressor cells (MDSCs) in multiple myeloma (MM) in the context of autologous stem cell transplantation (ASCT). (biomedcentral.com)
  • Both MDSC phenotypes pre-ASCT but not post-ASCT similarly suppressed in vitro autologous T and natural killer T cell proliferation. (biomedcentral.com)
  • We propose that targeting CSF1R on these cells may improve the results of ASCT in MM. (biomedcentral.com)
  • The occurrence of varicella zoster virus (VZV) reactivation is increased after allogeneic transplantation, whereas limited data are available for herpes zoster (HZ) after autologous SCT (ASCT). (nature.com)
  • Lower specific antibody titers at transplantation were observed in patients with HZ after ASCT than in those without reactivation ( P =0.009). (nature.com)
  • Finally, OS was better in myeloma patients with HZ after ASCT compared with patients without HZ ( P =0.007). (nature.com)
  • Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). (haematologica.org)
  • Is HDT-ASCT the only option in the frontline for multiple myeloma treatment? (janssen.com)
  • High-risk patients do not benefit from stem cell transplant and should be offered alternative therapies. (elsevierpure.com)
  • In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
  • antibody-drug conjugates, immune checkpoint therapy, adoptive cell therapies such as natural killer cells, marrow infiltrating lymphocytes, dendritic cells, CAR T cell therapies and cancer vaccines represent the basis for next generation myeloma therapies. (trialx.com)
  • Innovation in this area of medicine has been needed, and today's approval of [motixafortide] addresses the demand for new therapies that can meet today's challenges by delivering more reliability in stem cell mobilization, [vs] filgrastim alone, with fewer days of apheresis sessions and fewer doses of filgrastim for people living with this cancer. (cancernetwork.com)
  • Ajai Chari, MD, discusses the evolving landscape and developing therapies within multiple myeloma. (onclive.com)
  • After his disease went into remission again, this patient has now received 2 different T-cell-redirection therapies when those remissions ended. (onclive.com)
  • Historically, in multiple myeloma, to receive accelerated approval for a new drug for patients with an unmet need (ie, those who had exhausted all available therapies), you needed a 20% to 30% response rate for 3 to 4 months. (onclive.com)
  • Now we have game-changing T-cell-redirecting therapies, such as CAR [chimeric antigen receptor] T-cell therapies and bispecific antibodies," he explained. (onclive.com)
  • T-cell-redirection therapies are now giving anywhere from 60% to 100% response rates that are lasting upward of 9 months to we don't even know how long, because they're so durable. (onclive.com)
  • Evidence indicates that residual cancer cells contaminate autologous grafts and may contribute to early relapses after autologous stem cell transplantation. (elsevierpure.com)
  • Large numbers of myeloid-derived suppressor cells (MDSCs), a mixture of monocytic and granulocytic cells, accumulate during many pathologic conditions, including cancer, infectious diseases, trauma, and sepsis. (biomedcentral.com)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Multiple myeloma is a blood cancer that starts in the plasma cells in the bone marrow. (medlineplus.gov)
  • As the cancer cells grow in the bone marrow, you may have bone pain, most often in the ribs or back. (medlineplus.gov)
  • The cancer cells can weaken bones. (medlineplus.gov)
  • Multiple myeloma (MM) is a cancer of terminally differentiated plasma B cells that originates in the hematopoietic bone marrow and accounts for 15%-20% of all hematologic malignancies ( 1 , 2 ). (snmjournals.org)
  • Our scientific fraternity achieved a lot this year in the field of cancer treatment, giving new ray of hope to cancer patients with advances in immunotherapy, stem cell transplants and genomic testing. (trialx.com)
  • FDA approval of the breakthrough CAR-T cell therapy for cancer brings the first approved gene therapy treatment to the United States. (trialx.com)
  • It reprograms the body's own immune system to recognise and kill cancer cells. (trialx.com)
  • The therapy initially called CAR-T cell immunotherapy and now named Kymriah by Novartis, is approved to treat children and young adults with a recurrent form of the blood cancer called acute lymphoblastic leukemia (ALL). (trialx.com)
  • The discussion highlighted the opportunity that these engineered immune cells present to cancer treatment and possible use in treatment of other cancers. (trialx.com)
  • We talked to Dr. Saad Usmani of Levine Cancer Institute / Carolinas Healthcare System about the latest advances in immunotherapy for multiple myeloma. (trialx.com)
  • Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
  • By blocking the CXCR4 receptor, motixafortide was shown in a Phase 2 study in pancreatic cancer patients to enhance anti-tumoral activity and to ameliorate the pro-tumoral activities by modulating the effector/suppressor cell ratio towards a proinflammatory profile. (fox5sandiego.com)
  • Dimeo FC, Tilmann MH, Bertz H, Kanz L, Mertelsmann R, Keul J: Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. (karger.com)
  • Adding thalidomide to a standard regimen of high-dose chemotherapy in patients with the cancer multiple myeloma improved complete responses but did not give any advantage in five-year survival, according to a study published in the New England Journal of Medicine (March 9). (pharmatimes.com)
  • Given the strong efficacy data shown in the GENESIS trial, which included patients who are representative of the current multiple myeloma patient population, we believe [motixafortide] will play a critical role in addressing unmet needs and introduce a new treatment paradigm for this challenging cancer," Serlin stated. (cancernetwork.com)
  • Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice. (cancernetwork.com)
  • This study was supported by the Dutch Cancer Society, the European Myeloma Network, and by unrestricted grants from Celgene and Janssen. (medpagetoday.com)
  • RÉSUMÉ Le myélome multiple est un cancer systémique caractérisé par des cellules plasmatiques anormales, qui peut être traité par des agents chimiothérapeutiques et par irradiation, mais qui est rarement curable. (who.int)
  • Multiple myeloma (MM) is a cancer of the The largest series, 23 patients with lepto- plasma cells. (who.int)
  • ABSTRACT Multiple myeloma (MM) is a systemic malignancy of pathologic plasma cells that is treat able with chemotherapeutic agents and irradiation, but rarely curable. (who.int)
  • Patients who present with active (symptomatic) multiple myeloma are treated with induction therapy. (medscape.com)
  • Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
  • This ex vivo rabbit-specific oncolytic poxvirus called myxoma virus treatment also effectively inhibits systemic in vivo engraftment of human myeloma cells into immunodeficient mice and results in efficient elimination of primary CD138 + myeloma cells contaminating patient hematopoietic cell products. (elsevierpure.com)
  • In general, the first decision made in the management of patients with myeloma who require systemic therapy is whether stem cell transplantation is part of the strategy. (medscape.com)
  • However, due to complex and varied systemic symptoms, including inflammatory storm, sepsis, acute respiratory failure, tachycardia, coagulopathy, and other extrapulmonary organ injuries, she died 19 days after signs due to severe respiratory failure and multiple organ failure. (flu.org.cn)
  • Multiple myeloma (MM) represents 1% of all cancers and is the second most common hematologic malignancy, after lymphoma. (scielo.br)
  • Multiple Myeloma (MM) is an incurable plasma cell malignancy that accounts for 18% of all hematologic malignancies. (haematologica.org)
  • Multiple myeloma (MM) is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma (MM). We evaluated 126 MM patients for t(4;14) or t(11;14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. (elsevierpure.com)
  • Here, we demonstrate that ex vivo treatment with an oncolytic poxvirus called myxoma virus results in specific elimination of human myeloma cells by inducing rapid cellular apoptosis while fully sparing normal hematopoietic stem and progenitor cells. (elsevierpure.com)
  • The specificity of this elimination is based on strong binding of the virus to myeloma cells coupled with an inability of the virus to bind or infect CD34 + hematopoietic stem and progenitor cells. (elsevierpure.com)
  • Early fate decisions in hematopoietic stem and progenitor cells. (lu.se)
  • Thirty-eight patients (4.83%) had pathologic findings before transplantation. (slideshare.net)
  • A 59-year-old man with a history of IgG kappa multiple myeloma presented to an outpatient facility for evaluation of left hip pain, which was found to be a pathologic fracture. (medscape.com)
  • NCCN clinical practice guidelines in oncology: multiple myeloma. (medlineplus.gov)
  • Arvin AM . Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. (nature.com)
  • Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. (smw.ch)
  • Ajai Chari, MD, professor of medicine and the director of clinical research in the multiple myeloma (MM) program at the Icahn School of Medicine at Mount Sinai in New York, NY, saw an opportunity to contribute from the earliest days of the COVID-19 pandemic. (onclive.com)
  • Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. (haematologica.org)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • The approval of new drugs continues to change the landscape of myeloma maintenance therapy. (medscape.com)
  • Alkylator and nitrosourea therapy is usually deferred or reduced in patients who may require autologous stem cell collection, to avoid injury to the stem cells. (medscape.com)
  • Post-transplantation maintenance therapy with low-dose lenalidomide yields improved PFS and overall survival (OS). (medscape.com)
  • The intrinsic immune dysfunction in combination with therapy-related immunosuppression leads to an increased risk for infections, which is a hallmark of multiple myeloma (MM) and major cause of mortality [ 1 - 5 ]. (jcancer.org)
  • Minimal residual disease (MRD) refers to the small number of malignant cells that remain after therapy when the patient is in remission and shows no symptoms or overt signs of disease. (smw.ch)
  • We discussed Dr. Junes CAR-T cell journey to understand nuances of the new therapy. (trialx.com)
  • Listen to the talk on CAR- T cell therapy with Dr. June HERE! (trialx.com)
  • In 2017 stem cell transplants remains a key option for treatment of eligible multiple myeloma patients, and in majority of patients it is done as a part of frontline therapy. (trialx.com)
  • Researchers believe that MRD testing could help them compare myeloma therapy strategies, evaluate new treatments faster, and guide treatment decisions. (trialx.com)
  • Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received. (cancernetwork.com)
  • Experts in the field of multiple myeloma gathered to discuss treatment options, including bispecific antibodies, CAR T-cell therapy, and current and future FDA approvals for treatments. (cancernetwork.com)
  • Cell Replacement Therapy for Parkinson's Disease - Evaluating the potential of autologous grafting. (lu.se)
  • The presence of inflammatory cytokines after high-dose chemotherapy leads to proliferation and activation of MDSCs originating from autologous hematopoietic progenitors at the time of engraftment. (biomedcentral.com)
  • The damage caused by thalidomide was not mutually exclusive, with the majority of children exhibiting damage to multiple organs and tissues [ 3 , 7 ]. (hindawi.com)
  • Last year, Celgene was forced to discontinue a trial of a thalidomide derivative - Revlimid (lenalidomide) - in multiple myeloma patients after patients developed blood clots. (pharmatimes.com)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Plasma cells help your body fight infection by producing proteins called antibodies . (medlineplus.gov)
  • A type and antibody screen specimen obtained before the transfusions revealed that his red cells were type B positive, a screen for unexpected antibodies was negative, and direct antibody tests (DAT) for both anti-IgG and anti-C3b were also negative. (medscape.com)
  • Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. (smw.ch)
  • MDSCs are characterized by myeloid origin, immature state, and most importantly by their potent ability to suppress different aspects of immune responses, especially T cell proliferation and cytokine production [ 7 ]. (biomedcentral.com)
  • Motixafortide leverages the expression of the CXCR4 receptor on different immune cells and potentiates the immune system against the tumor. (kron4.com)
  • Among CXCR4-expressing immune cells, some exhibit anti-tumoral activity, such as effector T cells and some exhibit pro-tumoral activity and support tumor growth. (fox5sandiego.com)
  • Stem Cell Research Advances , edn. (edu.au)
  • Patients with monoclonal gammopathy of unknown significance, smoldering MM, plasma cell leukemia and amyloidosis were excluded. (scielo.br)
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
  • Leukemia is a malignant condition involving the excess production of immature or abnormal leukocytes, which eventually suppresses the production of normal blood cells and results in symptoms related to cytopenias. (msdmanuals.com)
  • Furthermore, the infection itself can pathogenetically contribute to the progression of MM through different mechanisms, such as robust production of promyeloma cytokines (e.g., interleukin-6) and activation of Toll-like receptors on malignant plasma cells [ 6 - 10 ]. (jcancer.org)
  • First described in 1848, MM is characterized by a proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraprotein (M protein). (medscape.com)
  • Research shows that stem cell transplants significantly increases the amount of time, for which a patient has their disease under control. (trialx.com)
  • He has had 2 autologous stem cell transplants, 7 years and 1 year ago. (medscape.com)
  • Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. (scielo.br)
  • The diagnosis was established according to International Myeloma Working Group criteria [ 12 ]. (jcancer.org)
  • Chari's longtime mentor and colleague Sundar Jagannath, MBBS, director of the Center of Excellence for Multiple Myeloma at Mount Sinai, believes his mentee's work on this study sums up Chari very well. (onclive.com)
  • Monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. (medscape.com)
  • Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. (snmjournals.org)
  • The cer is about 2%-5% and as high as 26% in most common complications include renal small-cell lung carcinoma [ 5 ]. (who.int)
  • Two weeks before the current visit, he received a transfusion of 2 units of red blood cells to treat anemia , but complications were documented. (medscape.com)